Neurology

When is a primary care patient with back pain ready for referral to PM&R? No formulas available but basic principles hold true and earlier is always better.

A daily dose of clinical news you may have missed.

The highest risk of mortality among a Danish population with dementia occurred within 2 weeks of an opioid prescription but remained significant at 180 days.

Disparities in emergency routing persisted despite women being acutely sicker than men and living the same distance from a comprehensive stroke center, in a Houston, Tx study.

Howard Fillit, MD, cofounder/chief scientific officer of the Alzheimer Drug Discovery Foundation, says lecenumab's approval opens the door for future drug development.

Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.

An overview of common headache conditions and treatments for primary care clinicians, here.

Your daily dose of clinical news you may have missed.

FDA's action, based on confirmatory evidence showing slowed disease progression, follows a January 2023 accelerated approval.

Wellbeing is considered a measurable and modifiable community attribute that study authors show is correlated with CV outcomes.

Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.

Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

Your daily dose of clinical news you may have missed.

Results also showed that prediabetes is associated with dementia risk but this risk was explained by the subsequent development of diabetes.

A Feinberg School of Medicine physiatrist with long experience assessing long COVID talks specifically about common neurologic sequelae of the infection.

Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.

Menstrual migraine is often described as more disabling than non-menstrual migraine. Get an overview and test your knowledge, here.

Bayer's investigational FXIa inhibitor is currently being studied in a large-scale phase 3 development program expected to enroll more than 27 000 participants.

Your daily dose of clinical news you may have missed.

In a unique pharmacodynamic study, nalmefene demonstrated rapid reversal of respiratory depression from the synthetic opioid remifentanil and sustained duration of action.

Your daily dose of clinical news you may have missed.

The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.

Findings also showed that between 1990 and 2019, the global number of ischemic stroke deaths rose from 2 million to 3 million.

Scott Laker, MD, vice president of the AAPM&R, offers 3 thoughts on what primary care clinicians should think of when they think about PM&R.

Brexpiprazole, an atypical antipsychotic, is the first and only medication approved to treat AD-associated agitation, reported in almost half of people with the disease.

The partnership between primary care and PM&R is a tool in each specialty's tool box, with the patient's return to full function the shared goal.

A diagnosis of concussion in an 8-year-old who plays weekend soccer is, on its face, bad news; the good news is that 15 years ago, it might have gone unnoticed, untreated.

The vice president of the American Academy of Physical Medicine & Rehabilitation played a significant role in developing early concussion programs and educating clinicians and coaches.

The role of the trigeminal nerve and its connection to the brainstem has led to a greater understanding of where migraine pain originates. Expert explains, here.

Eli Lilly's investigational drug targeting amyloid plaque slowed clinical decline by 35% in participants with early symptomatic Alzheimer disease at 18 months, the company announced.